The Breakthrough Therapies Act could spur research and improve access to life-saving drugs

In Politics by Michael Rae

In March 2023, Sens. Cory Booker (D-NJ) and Rand Paul (R-KY) reintroduced the Breakthrough Therapies Act, which aims to remove regulatory barriers that limit research and access to potentially life-saving treatments that are heavily restricted by Schedule I of the Controlled Substances Act (CSA). If passed, the bill would modify the current CSA by allowing automatic rescheduling of substances with “breakthrough therapy” designation, such as MDMA and psilocybin, from Schedule I to Schedule II. 

In recent years, psychedelics, such as MDMA and psilocybin, have demonstrated exceptional potential in treating an array of mental health conditions, ranging from treatment-resistant suicidal depression and

Read more at Reason.org